Senseonics (NYSE:SENS) Reaches New 52-Week High – What’s Next?

Shares of Senseonics Holdings, Inc. (NYSE:SENS) reached a new 52-week high during trading on Tuesday . The company traded as high as $1.20 and last traded at $1.06, with a volume of 18589708 shares. The stock had previously closed at $1.13.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $2.00 price objective on shares of Senseonics in a research note on Friday, November 15th. StockNews.com assumed coverage on shares of Senseonics in a research note on Thursday, December 26th. They issued a “sell” rating for the company.

Senseonics Stock Down 6.2 %

The company has a market cap of $631.05 million, a PE ratio of -8.15 and a beta of 0.64. The stock’s 50 day moving average price is $0.50 and its 200-day moving average price is $0.42. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47.

Senseonics (NYSE:SENS) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. The business had revenue of $4.26 million during the quarter, compared to analysts’ expectations of $4.02 million. On average, analysts predict that Senseonics Holdings, Inc. will post -0.14 earnings per share for the current year.

Insider Activity at Senseonics

In related news, CFO Frederick T. Sullivan acquired 124,933 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $0.38 per share, for a total transaction of $47,474.54. Following the acquisition, the chief financial officer now owns 2,478,844 shares of the company’s stock, valued at $941,960.72. This trade represents a 5.31 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Timothy T. Goodnow acquired 315,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was bought at an average price of $0.31 per share, with a total value of $97,650.00. Following the completion of the acquisition, the chief executive officer now directly owns 11,310,355 shares in the company, valued at approximately $3,506,210.05. This represents a 2.86 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SENS. FMR LLC raised its holdings in Senseonics by 48,267.2% in the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after purchasing an additional 167,970 shares in the last quarter. Ridgecrest Wealth Partners LLC bought a new position in Senseonics in the 4th quarter worth $60,000. GSA Capital Partners LLP bought a new position in shares of Senseonics in the 3rd quarter worth about $117,000. Symmetry Partners LLC bought a new position in shares of Senseonics in the 3rd quarter worth about $164,000. Finally, Cubist Systematic Strategies LLC increased its stake in shares of Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after acquiring an additional 85,501 shares in the last quarter. 12.36% of the stock is currently owned by institutional investors.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.